Financials
Financial year 2025
Amophar OTC from Schelle, company number BE0795483142, closed financial year 2025 with a result of € 3,725 after tax. For that financial year Amophar OTC recorded a gross margin of € 4,288 and equity of € 15,024. Compared with financial year 2024, the result moved from € 170 to € 3,725. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.
€ 15,024
▲ 33% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 3,725
▲ € 3,555 vs 2024
Profit after tax over the fiscal year.
€ 345
▼ 99% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 5,024.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 247,838
▲ € 235,291 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 9,965
▲ 7% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 4,408 | € -1,718 | € 4,288 | ▲ € 6,006 |
| Profit after taxes | € 1,130 | € 170 | € 3,725 | ▲ € 3,555 |
| Equity | € 11,130 | € 11,300 | € 15,024 | ▲ 33% |
| Total debts | € 471,651 | € 147,295 | € 257,803 | ▲ 75% |
| Cash | € 1,147 | € 29,364 | € 345 | ▼ 99% |
| Retained profit | € 1,130 | € 1,300 | € 5,024 | ▲ 286% |
| Balance sheet total | € 482,781 | € 158,595 | € 272,827 | ▲ 72% |
Key figures of Amophar OTC, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Amophar OTC?
What happened at Amophar OTC in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 3,725 (▲ € 3,555 vs 2024). Source: NBB ↗
- New establishment in Schelle. KBO
- LBS Besloten Vennootschap became a director. NBB
- INPHAGRO Besloten Vennootschap became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 1,130 profit in 2023 to € 3,725 profit in 2025.
Paid € 1,675 in corporate taxes since 2023.
Best year ever: 2025, with € 3,725 profit.
A new publication or filing at Amophar OTC? We notify you, reason included.
Follow Amophar OTCDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Amophar OTC are LBS Besloten Vennootschap and INPHAGRO Besloten Vennootschap. The shares are held by INPHAGRO.
Directors
According to the 2025 annual accounts
Director · represented by Asselman Lode
Also active at: L4P Invest, WOLFMAN, AMOPHAR, ALL-in-1
since 2022
INPHAGRO Besloten Vennootschap
Director · represented by Mc Cullough Sean
Also active at: LIFE MEDICAL, LIFE MEDICAL SOLUTIONS, FIDELMED, Protexx, Life International, AMOPHAR, ALL-in-1, KDT Consulting
since 2022
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Molenberglei 36
2627 Schelle
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →LIFE MEDICAL same network
€ 384,578 gross margin · 2025
INPHAGRO same network
€ 79,500 revenue · 2025
WOLFMAN same network
€ 126,568 gross margin · 2025
AMOPHAR same network
€ 83,196 gross margin · 2025
ALL-in-1 same network
€ 26.3 million revenue · 2025
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0795.483.142
- VAT number
- BE 0795.483.142
- Registered office
- Molenberglei 36, 2627 Schelle
- Names & denominations
- Amophar OTC · Amophar
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 December 2022
- Peppol
- Active · Active since 22 Oct 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen